One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema-Reference-Cited by-同舟云学术

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema

Published:2021-05 Issue: Volume:Volume 15 Page:1971-1978
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Tran Thi Ha Chau,Erginay Ali,Verdun Stephane^ORCID,Fourmaux Eric,Le Rouic Jean-François,Uzzan Joel^ORCID,Milazzo Solange,Baillif Stephanie^ORCID,Kodjikian Laurent

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference27 articles.

1. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

2. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment

3. Intravitreal Aflibercept for Diabetic Macular Edema

4. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema

5. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data;European Journal of Ophthalmology;2024-03-11

2. A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes;Ophthalmology Retina;2022-12

3. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?;Expert Opinion on Biological Therapy;2022-07-17

4. Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema;Clinical Ophthalmology;2022-03